65,437 trials
Colorectal Adenocarcinoma · Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Overall Response Rate (ORR) — 2; 16 Participants
HIV/AIDS · Contraception
Primary: Proportion of Participants That Ovulate During Month 3 — 11; 0 Participants — p=<.001
Cancer of Prostate
Primary: Feasibility - Site Level: Medical Center Director (MCD) Approval — 3; 1 sites
Chlamydia Trachomatis Infection
Primary: Response Rate at Recruitment — 100; 100 Participants
Chronic Low Back Pain
Primary: Program Initiation (e.g., Reach) — 16; 15 Participants — p=1.0
Surgery
Primary: Tolerance to Preop Placement as Assessed by Likert Scale — 0; 10; 0; 10 units on a scale (0-10)
Stroke
Primary: Modified Ordinal Rankin Scale (mRS) — 16; 11; 21; 23 Participants
Presbyopia · Refractive Errors · Eye Diseases
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 74.0; 75.5; 4.3 percentage of participants — p=<0.0001
Pathological Gambling · Gambling Disorder
Primary: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) — -11.76; -11.86 units on a scale
Solid Tumor
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 85; 1; 0; 23 Participants
Melanoma
Primary: Determine Sensitivity of Blood-Based Assay
Septic Shock · Acute Kidney Injury
Primary: Change in Plasma Renin Levels — -15; 69; -6; 26 pg/mL
Overactive Detrusor · Neurogenic Bladder
Primary: Change From Baseline in Percent of Catheterizations Without a Leaking Accident at Week 6 — -0.45; 16.91; 13.82; 15.32 percentage of point — p=0.0928
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Non-Hodgkin Lymphoma · Ann Arbor Stage IV Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 0 percentage of patients
Infant Development · Motivation
Primary: Change in Infant Food Reinforcing Proportion — 0.66; 0.64; 0.53; 0.54 proportion food response/total response — p=0.016